Cefuroxime

DRUG INFORMATION

  ADULT
    - Tablets and oral suspension are not bioequivalent and are therefore not
      substitutable on a milligram-per-milligram basis. ( 2.1 ) Administer tablets with
      or without food. ( 2.2 ) Administer cefuroxime axetil tablets as described in the
      dosage guidelines. ( 2.2 ) Dosage adjustment is required for patients with
      impaired renal function.
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Tablets and oral suspension are not bioequivalent and are therefore not
      substitutable on a milligram-per-milligram basis. ( 2.1 ) Administer tablets with
      or without food. ( 2.2 ) Administer cefuroxime axetil tablets as described in the
      dosage guidelines. ( 2.2 ) Dosage adjustment is required for patients with
      impaired renal function.
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Therefore, patients who cannot swallow the tablet whole should receive the oral
      suspension. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval
      adjustment is required for patients whose creatinine clearance is less than 30
      mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by
      the kidney [see Clinical Pharmacology (12.3) ].
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for cefuroxime (Cefuroxime
      Axetil), section 'dosage and administration', retrieved 2026-08-29
    - Dosing in Adults with Renal Impairment Creatinine Clearance (mL/min) Recommended
      Dosage ≥30 No dosage adjustment 10 to <30 Standard individual dose given every 24
      hours <10 (without hemodialysis) Standard individual dose given every 48 hours
      Hemodialysis A single additional standard dose should be given at the end of each
      dialysis
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'dosage and
      administration', retrieved 2026-08-29
    - Because elderly patients are more likely to have decreased renal function, care
      should be taken in dose selection, and it may be useful to monitor renal function.
      8.6 Renal Impairment Reducing the dosage of cefuroxime axetil is recommended for
      adult patients with severe renal impairment (creatinine clearance <30 mL/min) [see
      Dosage and Administration (2.5) , Clinical Pharmacology (12.3) ] .
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for cefuroxime (Cefuroxime
      Axetil), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Available data from published epidemiologic studies, case series, and
      case reports over several decades with cephalosporin use, including cefuroxime
      axetil, in pregnant women have not established drug-associated risks of major
      birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) .
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'pregnancy',
      retrieved 2026-08-29
    - In studies in pregnant mice and rats administered oral cefuroxime axetil during
      organogenesis at 14 and 9 times the maximum recommended human dose (MRHD) based on
      body surface area, respectively, there were no adverse developmental outcomes (see
      Data).
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'pregnancy',
      retrieved 2026-08-29
    - The estimated background risk of major birth defects and miscarriage for the
      indicated populations are unknown.
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Risk Summary Based on several published case reports describing multiple lactating
      women who received cefuroxime via intravenous, intramuscular, and oral routes,
      cefuroxime is present in human milk.
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'nursing
      mothers', retrieved 2026-08-29
    - The highest maternal milk concentration described occurred in lactating women 8
      hours after an intramuscular administration of cefuroxime 750 mg.
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'nursing
      mothers', retrieved 2026-08-29
    - Allowing for an infant milk consumption of 150 mL/kg/day, the estimated breastfed
      infant dose would be less than 1% of the adult dose .
      Source: US FDA label for cefuroxime (Cefuroxime Axetil), section 'nursing
      mothers', retrieved 2026-08-29